New MDMA variants could be promising alternatives for safe psychotherapeutic applications

FHS
June 25, 2024
3:05 pm

The use of the active ingredient 3,4-methylenedioxy-N-methylamphetamine (MDMA), commonly known as “ecstasy”, to support psychotherapy for mental illnesses such as post-traumatic stress disorder is being discussed worldwide.

More beef in the gene editing space

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, more beef

November 22, 2024

Hidden threats in plant-based diets: Rising allergies to lesser-known legumes

Researchers have identified emerging legume allergens like peas, lentils, and lupines, calling for more extensive studies and better diagnostics to manage increasing allergic reactions. The

July 15, 2024

What Will It Take to Achieve Value From Digitally Enabled Diabetes Care?

Tony Vahedian, CEO at CCS A report from the Peterson Health Technology Institute (PHTI) found that many digital diabetes management platforms aren’t providing meaningful ROI for

June 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.